  <Trial>
    <Internal_Number>2452965</Internal_Number>
    <TrialID>EUCTR2004-001298-24-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using intravenous injections of RO0503821 in patients with chronic kidney disease who are on dialysis</Public_title>
    <Scientific_title>An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using intravenous injections of RO0503821 in patients with chronic kidney disease who are on dialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>F. Hoffmann-La Roche Ltd</Primary_sponsor>
    <Date_registration3>20040628</Date_registration3>
    <Date_registration>28/06/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001298-24                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/07/2004</Date_enrollement>
    <Target_size>168</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Baseline predialysis (for HD patients) Hb concentration 8-11 g/dL determined from the mean of 2 screening values with at least one day between measurements&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Previous therapy with recombinant human erythropoetin or any other erythropoeitc substance within 12 weeks prior to screening. If epoetin treatment has been interrupted for at least 12 weeks, the patient may be enrolled in the study. Ongoing epoetin treatment should not be discontinued to allow participation in the trial.&lt;br&gt;</Exclusion_Criteria>
    <Condition>anemia in chronic kidney patients who are in dialysis</Condition>
    <Intervention>&lt;br&gt;Product Name: cera&lt;br&gt;Product Code: RO 0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: Neorecormon&lt;br&gt;Product Name: Neorecormon&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Epoetin beta&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50000-&lt;br&gt;INN or Proposed INN: epoetin beta&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100000-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate the efficay of IV RO 0503821;Secondary Objective: - To asses time to response&lt;br&gt;- To asses the safety and tolerability of multiple doses of RO 0503821 during the correction and extension periods in this patient population&lt;br&gt;- To asses long term safety with RO 0503821 in this patient population&lt;br&gt;- To investigate the farmachokinetics and the concentration-effect relationships after IV administration of RO 0503821 in this patient population;Primary end point(s): To demonstrate the efficay of IV RO 0503821 treatment for correction of anemia in patients with kidney chronic disease who are on dialysis</Primary_outcome>
    <Secondary_ID>BA16736</Secondary_ID>
  </Trial>